People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. | — | Biotechnology | Series D+ | $162.6M | $4.1B | 2018 |
| Cedilla Therapeutics, Inc. | — | Biotechnology | Series C | $82.6M | $3.1B | 2020 |
| Goldfinch Bio, Inc. | — | Pharmaceuticals | Series C | $69.7M | $2.4B | 2020 |
| Seventh Sense Biosystems, Inc. | — | Biotechnology | Series B | $62.9M | $732.6M | 2012 |
| Rhythm Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $60.5M | $696.2M | 2015 |
NEIL EXTER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside NEIL EXTER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ABBIE CELNIKER | 2 | 6 |
| Robert Langer | 1 | 36 |
| Alan Crane | 1 | 9 |
| Hoyoung Huh | 1 | 7 |
| Harry Wilcox | 1 | 6 |
| Jake Simson | 1 | 6 |
| Eli Casdin | 1 | 6 |
| Doug Cole | 1 | 6 |
| Keith Gottesdiener | 1 | 4 |
| Alexandra Glucksmann | 1 | 4 |
| PETER HUTT | 1 | 4 |
| Charles Homcy | 1 | 4 |
| Timothy Richards | 1 | 4 |
| Kevin Raidy | 1 | 4 |
| R. ROX ANDERSON | 1 | 3 |
| Jonathan T. Silverstein | 1 | 3 |
| Edward T. Mathers | 1 | 3 |
| Wen Chen | 1 | 3 |
| Chris Bowden | 1 | 3 |
| Gayle Crowell | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.